Compass Pathways PLC
NASDAQ:CMPS
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
4.52
12.37
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CMPS stock under the Base Case scenario is 2.8061 USD. Compared to the current market price of 4.9314 USD, Compass Pathways PLC is Overvalued by 43%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Compass Pathways PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CMPS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Compass Pathways PLC
Balance Sheet Decomposition
Compass Pathways PLC
Current Assets | 233.7m |
Cash & Short-Term Investments | 207m |
Receivables | 13m |
Other Current Assets | 13.7m |
Non-Current Assets | 13.7m |
PP&E | 2.7m |
Other Non-Current Assets | 10.9m |
Current Liabilities | 26.2m |
Accounts Payable | 8.2m |
Accrued Liabilities | 15.8m |
Other Current Liabilities | 2.2m |
Non-Current Liabilities | 28.1m |
Long-Term Debt | 27.6m |
Other Non-Current Liabilities | 459k |
Earnings Waterfall
Compass Pathways PLC
Revenue
|
0
USD
|
Operating Expenses
|
-168.2m
USD
|
Operating Income
|
-168.2m
USD
|
Other Expenses
|
23.9m
USD
|
Net Income
|
-144.3m
USD
|
Free Cash Flow Analysis
Compass Pathways PLC
USD | |
Free Cash Flow | USD |
CMPS Profitability Score
Profitability Due Diligence
Compass Pathways PLC's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Compass Pathways PLC's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
CMPS Solvency Score
Solvency Due Diligence
Compass Pathways PLC's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Score
Compass Pathways PLC's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CMPS Price Targets Summary
Compass Pathways PLC
According to Wall Street analysts, the average 1-year price target for CMPS is 38.9866 USD with a low forecast of 22.22 USD and a high forecast of 126 USD.
Dividends
Current shareholder yield for CMPS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Compass Pathways Plc functions as an investment holding company. The company is headquartered in Altrincham, Cheshire and currently employs 116 full-time employees. The company went IPO on 2020-09-18. The firm is focused on treatment-resistant depression (TRD). The company is developing COMP360, a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. Its COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications. The psilocybin administration session lasts approximately six to eight hours, with patients supported by therapists in a non-directive manner. Psilocybin administration sessions are preceded by preparation sessions, in which patients are given a thorough orientation, and followed by integration sessions to help patients process the range of emotional and physical experiences facilitated by COMP360 administration.
Contact
IPO
Employees
Officers
The intrinsic value of one CMPS stock under the Base Case scenario is 2.8061 USD.
Compared to the current market price of 4.9314 USD, Compass Pathways PLC is Overvalued by 43%.